Increased BCL-2 family members, particularly BCL-xL levels have been connected to HCC growth [15] and sorafenib-resistance [16], validating the mitochondrial pathway as highly relevant in sorafenib therapy for HCC. The gene discussed is BCL2; the disease is hepatocellular carcinoma.